
    
      This is a phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group,
      comparative study (Treatment Period I) and a phase 3, multicenter, open-label, long-term
      study (Treatment Period II) to evaluate the efficacy and safety of trelagliptin when
      administered orally at a dose of 25 mg once weekly to patients with type 2 diabetes mellitus
      complicated by severe renal impairment or end-stage renal disease and inadequate glycemic
      control despite diet and/or exercise therapy (if given) or despite treatment with one
      antidiabetic drug in addition to diet and/or exercise therapy (if given).
    
  